A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Osteoarthritis

In brief

CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224,535 versus placebo and naproxen treatment in patients with OA knee pain.

Key facts

Study ID

NCT00418782

Run by

Pfizer

People needed

212

Starts

2007-01-01

Expected to finish

2007-08-01

Last updated by the study team

2018-12-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is a healthy adult 18 to 75 years of age, inclusive, in general good health and with diagnosis of knee OA, as determined by the American College of Rheumatology (ACR) clinical/radiographic classification criteria for OA of the knee.
• Women must be of non childbearing potential (amenorrhea for at least 1 year PLUS have a serum follicle stimulating hormone (FSH) level >30 IU/L, bilateral oophorectomy or hysterectomy), and have a confirmed negative serum pregnancy test at the screening visit prior to randomization.

You may not qualify if…

• History of other diseases that may involve the study joint, including inflammatory joint diseases, crystalline disease, endocrinopathies, metabolic diseases, infections, neuropathic disorders, avascular necrosis, Paget's disease, or tumors.
• Women of childbearing potential, or who are pregnant or lactating.

Where it is running

• Pfizer Investigational Site — Anniston, Alabama, United States
• Pfizer Investigational Site — Bayou La Batre, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Hot Springs, Arkansas, United States
• Pfizer Investigational Site — Northridge, California, United States
• Pfizer Investigational Site — Sacramento, California, United States
• Pfizer Investigational Site — Tarzana, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Westminster, Colorado, United States
• Pfizer Investigational Site — Clearwater, Florida, United States
• Pfizer Investigational Site — DeFuniak Springs, Florida, United States
• Pfizer Investigational Site — Destin, Florida, United States
• Pfizer Investigational Site — Pensacola, Florida, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Gurnee, Illinois, United States
• Pfizer Investigational Site — Avon, Indiana, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Gretna, Louisiana, United States
• Pfizer Investigational Site — Kenner, Louisiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Frederick, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.